Healthcare: Eli Lilly’s Big Announcement, Plus GlaxoSmithKline Cozies Up to 23andMe

<p>It’s big pharma week! First, we discuss Eli Lilly’s second quarter earnings and its decision to spin-off its animal health business. Then, we explain why GlaxoSmithKline became an investor in the DNA screening company, 23andMe.</p>